The filing is routine AGM-related with no immediate market-moving news. Traders should monitor the AGM vote on the capital band amendment, which could enable future equity issuance and potential dilution. The CEO transition is orderly but adds near-term management uncertainty. Pipeline catalysts (full VacSYn data H2 2026, ACI-24 interim H1 2026, NLRP3 inhibitor Phase 1 results H2 2026) are more relevant for medium-term valuation.
Price Chart
Executive Summary
AC Immune SA published its 2026 Annual General Meeting invitation, detailing the CEO transition from Andrea Pfeifer to interim CEO Martin Zügel, appointment of a Lead Independent Director, and proposed amendments to articles of association including a capital band of ~30% for 5 years. The filing also notes a consolidated net loss of CHF 70,447K for 2025 and extension of cash runway into Q4 2027 following a 30% workforce reduction. The AGM is scheduled for June 11, 2026.
Key Facts
- Dr. Andrea Pfeifer to retire as CEO after 23 years; Chair Martin Zügel appointed Interim CEO.
- Monika Bütler appointed Lead Independent Director for governance oversight.
- Board proposes introducing a capital band of CHF 2,202,018.50 to CHF 2,862,500.00 until June 2031 (~30% of outstanding capital).
- Conditional share capital for employee benefit plans to increase from CHF 86,683.80 to CHF 150,000.00 (up to 7,500,000 shares).
- Consolidated net loss for 2025: CHF 70,447K (IFRS); accumulated losses brought forward: CHF 424,441K.
- Cash runway extended to Q4 2027 after 30% workforce reduction in September 2025.
- Interim data from Phase 2 VacSYn trial of ACI-7104 showed positive immunogenicity, biomarker trends, and clinical measures in early Parkinson's disease.
Financial Impact
Net loss of CHF 70,447K for FY2025; accumulated losses CHF 424,441K
Risk Factors
- Potential dilution from capital band utilization up to ~30% of outstanding shares.
- Ongoing net losses without near-term revenue generation.
- Clinical trial risks for pipeline candidates (ACI-24, ACI-35, ACI-7104).
- CEO transition could cause temporary strategic uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0000950103-26-007252 |
| Document: dp246745_6k.htm | 0000950103-26-007252 |
| Document: 0000950103-26-007252-index-headers.html | 0000950103-26-007252 |
| Document: 0000950103-26-007252-index.html | 0000950103-26-007252 |
| Document: 0000950103-26-007252.txt | 0000950103-26-007252 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | 3/A | $2.45 $2.40 | ▼ −2.04% | ▼ −2.03% | $2.37 (−3.47%) |
Oct 9, 2026 17d ago | 3 | $2.50 $2.45 | ▼ −2.00% | ▼ −1.94% | $2.37 (−5.40%) |
Oct 2, 2026 24d ago | 6-K | $2.73 $2.71 | ▼ −0.55% | ▼ −1.22% | $2.37 (−13.21%) |
Sep 23, 2026 4w ago | 6-K | $2.83 $2.66 | ▼ −6.01% | ▼ −5.92% | $2.37 (−16.43%) |
Sep 3, 2026 7w ago | 6-K | $2.93 $2.86 | ▼ −2.39% | ▼ −2.00% | $2.37 (−19.28%) |
Aug 20, 2026 9w ago | 6-K | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.37 (−10.42%) |
Aug 20, 2026 9w ago | Press Release | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.37 (−10.42%) |
Aug 11, 2026 10w ago | 6-K | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.37 (−6.89%) |
Aug 11, 2026 10w ago | Press Release | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.37 (−6.89%) |
Aug 5, 2026 11w ago | 6-K | $2.29 $2.32 | ▲ +1.31% | ▲ +1.47% | $2.37 (+3.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers